Related Experiment Video
Updated: Jun 7, 2026
08:02
Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
Published on: April 25, 2016
Glucocorticoid's pharmacology: past, present and future
Stefania Gessi1, Stefania Merighi, Pier Andrea Borea
1Department of Clinical and Experimental Medicine, Interdisciplinary Center for the Study of Inflammation, Ferrara, Italy.
Current Pharmaceutical Design
|October 28, 2010
Summary
Glucocorticoids (GCs) are vital anti-inflammatory drugs, but cause side effects via transactivation. Selective agonists (SEGRAs) aim to separate anti-inflammatory transrepression from harmful transactivation for safer treatments.
Area of Science:
- Pharmacology
- Molecular Biology
- Immunology
Background:
- Glucocorticoids (GCs) are widely used anti-inflammatory and immunosuppressive drugs.
- Their therapeutic effects stem from inhibiting pro-inflammatory agents (transrepression).
- However, GCs cause adverse effects, particularly metabolic issues, due to gene transactivation.
Purpose of the Study:
- To review the mechanisms of Glucocorticoid action.
- To summarize the efficacy and side effect profiles of selective Glucocorticoid Receptor Agonists (SEGRAs).
- To discuss the clinical potential of SEGRAs.
Main Methods:
- Literature review of Glucocorticoid mechanisms.
- Analysis of studies on SEGRAs.
- Discussion of clinical implications.
Main Results:
- GCs exert effects through transrepression (beneficial) and transactivation (adverse).
- SEGRAs are designed to selectively activate transrepression while minimizing transactivation.
- SEGRAs show promise in separating therapeutic efficacy from side effects.
Conclusions:
- SEGRAs represent a promising therapeutic strategy to improve Glucocorticoid therapy.
- Further research is needed to fully understand and optimize SEGRAs for clinical use.
- SEGRAs offer a potential solution to the limitations of traditional Glucocorticoids.
More Related Videos
Related Concept Videos
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:22Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:26Cushing Syndrome I: Introduction
Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...